{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:06:02Z","timestamp":1793747162066,"version":"4.6.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004333","name":"La Jolla Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004333","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High dose vasopressors portend poor outcome in vasodilatory shock. We aimed to evaluate the impact of baseline vasopressor dose on outcomes in patients treated with angiotensin II (AT II).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Exploratory post-hoc analysis of the Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) trial data. The ATHOS-3 trial randomized 321 patients with vasodilatory shock, who remained hypotensive (mean arterial pressure of 55\u201370\u00a0mmHg) despite receiving standard of care vasopressor support at a norepinephrine-equivalent dose (NED)\u2009&gt;\u20090.2\u00a0\u00b5g\/kg\/min, to receive AT II or placebo, both in addition to standard of care vasopressors. Patients were grouped into low (\u2264\u20090.25\u00a0\u00b5g\/kg\/min; n\u2009=\u2009104) or high (&gt;\u20090.25\u00a0\u00b5g\/kg\/min; n\u2009=\u2009217) NED at the time of study drug initiation. The primary outcome was the difference in 28-day survival between the AT II and placebo subgroups in those with a baseline NED\u2009\u2264\u20090.25\u00a0\u00b5g\/kg\/min at the time of study drug initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 321 patients, the median baseline NED in the low-NED subgroup was similar in the AT II (n\u2009=\u200956) and placebo (n\u2009=\u200948) groups (median of each arm 0.21\u00a0\u00b5g\/kg\/min,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.45). In the high-NED subgroup, the median baseline NEDs were also similar (0.47\u00a0\u00b5g\/kg\/min AT II group, n\u2009=\u2009107 vs. 0.45\u00a0\u00b5g\/kg\/min placebo group, n\u2009=\u2009110,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.75). After adjusting for severity of illness, those randomized to AT II in the low-NED subgroup were half as likely to die at 28-days compared to placebo (HR 0.509; 95% CI 0.274\u20130.945,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). No differences in 28-day survival between AT II and placebo groups were found in the high-NED subgroup (HR 0.933; 95% CI 0.644\u20131.350,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.71). Serious adverse events were less frequent in the low-NED AT II subgroup compared to the placebo low-NED subgroup, though differences were not statistically significant, and were comparable in the high-NED subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This exploratory post-hoc analysis of phase 3 clinical trial data suggests a potential benefit of AT II introduction at lower doses of other vasopressor agents. These data may inform design of a prospective trial.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      : The ATHOS-3 trial was registered in the clinicaltrials.gov repository (no. NCT02338843). Registered 14 January 2015.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-023-04446-1","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T10:02:51Z","timestamp":1683280971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial"],"prefix":"10.1186","volume":"27","clinical-trial-number":[{"clinical-trial-number":"nct02338843","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Patrick M.","family":"Wieruszewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinaldo","family":"Bellomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence W.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kealy R.","family":"Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zarbock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish K.","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Deane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Ostermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Wunderink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Boldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stew","family":"Kroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuck R.","family":"Greenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Hodges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"4446_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1056\/NEJMc1314999","volume":"370","author":"J-L Vincent","year":"2014","unstructured":"Vincent J-L, De Backer D. Circulatory shock. N Engl J Med. 2014;370:582\u20133.","journal-title":"N Engl J Med"},{"key":"4446_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00134-018-5218-5","volume":"44","author":"K Maheshwari","year":"2018","unstructured":"Maheshwari K, Nathanson BH, Munson SH, Khangulov V, Stevens M, Badani H, et al. The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients. Intensive Care Med. 2018;44:857\u201367.","journal-title":"Intensive Care Med"},{"key":"4446_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13613-018-0448-9","volume":"8","author":"J-L Vincent","year":"2018","unstructured":"Vincent J-L, Nielsen ND, Shapiro NI, Gerbasi ME, Grossman A, Doroff R, et al. Mean arterial pressure and mortality in patients with distributive shock: a retrospective analysis of the MIMIC-III database. Ann Intensive Care. 2018;8:107.","journal-title":"Ann Intensive Care"},{"key":"4446_CR4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47:1181\u2013247.","journal-title":"Intensive Care Med"},{"key":"4446_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.chest.2017.12.021","volume":"154","author":"JC Jentzer","year":"2018","unstructured":"Jentzer JC, Vallabhajosyula S, Khanna AK, Chawla LS, Busse LW, Kashani KB. Management of refractory vasodilatory shock. Chest. 2018;154:416\u201326.","journal-title":"Chest"},{"key":"4446_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1213\/ANE.0000000000004343","volume":"130","author":"JH Chow","year":"2020","unstructured":"Chow JH, Abuelkasem E, Sankova S, Henderson RA, Mazzeffi MA, Tanaka KA. Reversal of vasodilatory shock: current perspectives on conventional, rescue, and emerging vasoactive agents for the treatment of shock. Anesth Analg. 2020;130:15\u201330.","journal-title":"Anesth Analg"},{"key":"4446_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJMoa1704154","volume":"377","author":"A Khanna","year":"2017","unstructured":"Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419\u201330.","journal-title":"N Engl J Med"},{"key":"4446_CR8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/CCM.0000000000003092","volume":"46","author":"JA Tumlin","year":"2018","unstructured":"Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018;46:949\u201357.","journal-title":"Crit Care Med"},{"key":"4446_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13613-019-0536-5","volume":"9","author":"KR Ham","year":"2019","unstructured":"Ham KR, Boldt DW, McCurdy MT, Busse LW, Favory R, Gong MN, et al. Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial. Ann Intensive Care. 2019;9:63.","journal-title":"Ann Intensive Care"},{"key":"4446_CR10","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1164\/rccm.201911-2172OC","volume":"202","author":"R Bellomo","year":"2020","unstructured":"Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, et al. Renin and survival in patients given angiotensin ii for catecholamine-resistant vasodilatory shock. A clinical trial. Am J Respir Crit Care Med. 2020;202:1253\u201361.","journal-title":"Am J Respir Crit Care Med"},{"key":"4446_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13054-020-2733-x","volume":"24","author":"R Bellomo","year":"2020","unstructured":"Bellomo R, Wunderink RG, Szerlip H, English SW, Busse LW, Deane AM, et al. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit Care. 2020;24:43.","journal-title":"Crit Care"},{"key":"4446_CR12","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1177\/0885066619872720","volume":"35","author":"A Wong","year":"2020","unstructured":"Wong A, Alkazemi A, Eche IM, Petri CR, Sarge T, Cocchi MN. A retrospective review of angiotensin II use in adult patients with refractory distributive shock. J Intensive Care Med. 2020;35:1490\u20136.","journal-title":"J Intensive Care Med"},{"key":"4446_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.chest.2020.08.2074","volume":"159","author":"PM Wieruszewski","year":"2021","unstructured":"Wieruszewski PM, Wittwer ED, Kashani KB, Brown DR, Butler SO, Clark AM, et al. Angiotensin II infusion for shock: a multicenter study of postmarketing use. Chest. 2021;159:596\u2013605.","journal-title":"Chest"},{"key":"4446_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0885066620972943","volume":"37","author":"SE Smith","year":"2022","unstructured":"Smith SE, Newsome AS, Guo Y, Hecht J, McCurdy MT, Mazzeffi MA, et al. A multicenter observational cohort study of angiotensin II in shock. J Intensive Care Med. 2022;37:75\u201382.","journal-title":"J Intensive Care Med"},{"key":"4446_CR15","doi-asserted-by":"publisher","first-page":"e0623","DOI":"10.1097\/CCE.0000000000000623","volume":"4","author":"M Quan","year":"2022","unstructured":"Quan M, Cho N, Bushell T, Mak J, Nguyen N, Litwak J, et al. Effectiveness of angiotensin II for catecholamine refractory septic or distributive shock on mortality: a propensity score weighted analysis of real-world experience in the medical ICU. Crit Care Explor. 2022;4:e0623.","journal-title":"Crit Care Explor"},{"key":"4446_CR16","first-page":"43","volume":"19","author":"LS Chawla","year":"2017","unstructured":"Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP, et al. Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc. 2017;19:43\u20139.","journal-title":"Crit Care Resusc"},{"key":"4446_CR17","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/CCM.0000000000005317","volume":"50","author":"GL Sacha","year":"2022","unstructured":"Sacha GL, Lam SW, Wang L, Duggal A, Reddy AJ, Bauer SR. Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock. Crit Care Med. 2022;50:614\u201323.","journal-title":"Crit Care Med"},{"key":"4446_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13613-018-0379-5","volume":"8","author":"GL Sacha","year":"2018","unstructured":"Sacha GL, Lam SW, Duggal A, Torbic H, Bass SN, Welch SC, et al. Predictors of response to fixed-dose vasopressin in adult patients with septic shock. Ann Intensive Care. 2018;8:35.","journal-title":"Ann Intensive Care"},{"key":"4446_CR19","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1177\/08850666221081836","volume":"37","author":"ND Jakowenko","year":"2022","unstructured":"Jakowenko ND, Murata J, Kopp BJ, Erstad BL. Influence of timing and catecholamine requirements on vasopressin responsiveness in critically ill patients with septic shock. J Intensive Care Med. 2022;37:1512\u20139.","journal-title":"J Intensive Care Med"},{"key":"4446_CR20","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/phar.2683","volume":"42","author":"A Scheibner","year":"2022","unstructured":"Scheibner A, Betthauser KD, Bewley AF, Juang P, Lizza B, Micek S, et al. Machine learning to predict vasopressin responsiveness in patients with septic shock. Pharmacotherapy. 2022;42:460\u201371.","journal-title":"Pharmacotherapy"},{"key":"4446_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13054-022-03911-7","volume":"26","author":"PM Wieruszewski","year":"2022","unstructured":"Wieruszewski PM, Khanna AK. Vasopressor choice and timing in vasodilatory shock. Crit Care. 2022;26:76.","journal-title":"Crit Care"},{"key":"4446_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/SHK.0000000000000426","volume":"44","author":"C Martin","year":"2015","unstructured":"Martin C, Medam S, Antonini F, Alingrin J, Haddam M, Hammad E, et al. Norepinephrine: not too much. Too Long Shock. 2015;44:305\u20139.","journal-title":"Too Long Shock"},{"key":"4446_CR23","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1378\/chest.12-1106","volume":"143","author":"SM Brown","year":"2013","unstructured":"Brown SM, Lanspa MJ, Jones JP, Kuttler KG, Li Y, Carlson R, et al. Survival after shock requiring high-dose vasopressor therapy. Chest. 2013;143:664\u201371.","journal-title":"Chest"},{"key":"4446_CR24","doi-asserted-by":"publisher","unstructured":"See EJ, Clapham C, Liu J, Khasin M, Liskaser G, Chan JW, et al. A pilot study of Angiotensin II as primary vasopressor in critically ill adults with vasodilatory hypotension. The acute renal effects of angiotensin II management in shock (ARAMIS) study. Shock [Internet]. 2023 [cited 2023 Apr 3];Publish Ahead of Print. https:\/\/doi.org\/10.1097\/SHK.0000000000002109","DOI":"10.1097\/SHK.0000000000002109"},{"key":"4446_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell JA, Walley KR, Singer J, Gordon AC, H\u00e9bert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877\u201387.","journal-title":"N Engl J Med"},{"key":"4446_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jcrc.2020.10.023","volume":"61","author":"ED Wieruszewski","year":"2021","unstructured":"Wieruszewski ED, Jones GM, Samarin MJ, Kimmons LA. Predictors of dysrhythmias with norepinephrine use in septic shock. J Crit Care. 2021;61:133\u20137.","journal-title":"J Crit Care"},{"key":"4446_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CCM.0000000000003544","volume":"47","author":"PJ Gleeson","year":"2019","unstructured":"Gleeson PJ, Crippa IA, Mongkolpun W, Cavicchi FZ, Van Meerhaeghe T, Brimioulle S, et al. Renin as a marker of tissue-perfusion and prognosis in critically ill patients. Crit Care Med. 2019;47:152\u20138.","journal-title":"Crit Care Med"},{"key":"4446_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/CCM.0000000000005143","volume":"50","author":"M Jeyaraju","year":"2022","unstructured":"Jeyaraju M, McCurdy MT, Levine AR, Devarajan P, Mazzeffi MA, Mullins KE, et al. Renin kinetics are superior to lactate kinetics for predicting in-hospital mortality in hypotensive critically ill patients. Crit Care Med. 2022;50:50\u201360.","journal-title":"Crit Care Med"},{"key":"4446_CR29","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1164\/rccm.202005-2050OC","volume":"203","author":"M K\u00fcllmar","year":"2021","unstructured":"K\u00fcllmar M, Saadat-Gilani K, Weiss R, Massoth C, Lagan A, Cort\u00e9s MN, et al. Kinetic changes of plasma renin concentrations predict acute kidney injury in cardiac surgery patients. Am J Respir Crit Care Med. 2021;203:1119\u201326.","journal-title":"Am J Respir Crit Care Med"},{"key":"4446_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13054-021-03725-z","volume":"25","author":"AH Flannery","year":"2021","unstructured":"Flannery AH, Ortiz-Soriano V, Li X, Gianella FG, Toto RD, Moe OW, et al. Serum renin and major adverse kidney events in critically ill patients: a multicenter prospective study. Crit Care. 2021;25:294.","journal-title":"Crit Care"},{"key":"4446_CR31","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1213\/ANE.0000000000005953","volume":"134","author":"M Meersch","year":"2022","unstructured":"Meersch M, Weiss R, Massoth C, K\u00fcllmar M, Saadat-Gilani K, Busen M, et al. The association between angiotensin II and renin kinetics in patients after cardiac surgery. Anesth Analg. 2022;134:1002\u20139.","journal-title":"Anesth Analg"},{"key":"4446_CR32","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jtcvs.2021.02.097","volume":"163","author":"JH Chow","year":"2022","unstructured":"Chow JH, Wittwer ED, Wieruszewski PM, Khanna AK. Evaluating the evidence for angiotensin II for the treatment of vasoplegia in critically ill cardiothoracic surgery patients. J Thorac Cardiovasc Surg. 2022;163:1407\u201314.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"4446_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13613-022-01021-9","volume":"12","author":"MA Ammar","year":"2022","unstructured":"Ammar MA, Ammar AA, Wieruszewski PM, Bissell BD, Long TM, Albert L, et al. Timing of vasoactive agents and corticosteroid initiation in septic shock. Ann Intensive Care. 2022;12:47.","journal-title":"Ann Intensive Care"},{"key":"4446_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jcrc.2018.12.007","volume":"50","author":"MK Abril","year":"2019","unstructured":"Abril MK, Khanna AK, Kroll S, McNamara C, Handisides D, Busse LW. Regional differences in the treatment of refractory vasodilatory shock using angiotensin II in high output shock (ATHOS-3) data. J Crit Care. 2019;50:188\u201394.","journal-title":"J Crit Care"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-023-04446-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T14:03:44Z","timestamp":1685455424000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-023-04446-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4446"],"URL":"https:\/\/doi.org\/10.1186\/s13054-023-04446-1","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"assertion":[{"value":"1 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ATHOS-3 was sponsored by La Jolla Pharmaceutical Company and conducted under full oversight of site-level or central institutional review boards and ethics committees, per regional requirement. Written informed consent was obtained from all patients or their legal surrogates prior to inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RB, KRH, and AMD, report no conflicts of interest. JHC, PMW, AKK, RGW, and DWB have previously served on a scientific advisory board for La Jolla Pharmaceutical Company. JHC, LWB, AKK, and DWB have served on the Speaker\u2019s Bureau for La Jolla Pharmaceutical Company. AZ and JHC have received consultant fees from La Jolla Pharmaceutical Company. AZ has received consultant fees from\u00a0Paion. AKK received research grant funding from La Jolla Pharmaceutical Company for the ATHOS-3 study and through the Wake Forest Center for Hypertension and Vascular Research for RAAS in septic shock. MO\u2019s institution received research funding from La Jolla Pharmaceutical Company. CRG and TH are employees of La Jolla Pharmaceutical Company. SK was an employee of La Jolla Pharmaceutical Company during the preparation of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}